Evidence map›Paper›PMID 35650393›Full record

ArticleCancer gene therapy2022

Global characterization of megakaryocytes in bone marrow, peripheral blood, and cord blood by single-cell RNA sequencing.

Weilong Zhang, Changjian Yan, Xiaoni Liu, Ping Yang, Jing Wang, Yingtong Chen, Weiyou Liu, Shaoxiang Li, Xiuru Zhang, Gehong Dong and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Weilong Zhang *Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 100191, Beijing, China.
Changjian Yan *The Second Affiliated Hospital of Fujian Medical University, 362000, Quanzhou, China.
Xiaoni LiuDepartment of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, 341000, Ganzhou, China.
Ping YangDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, 100191, Beijing, China.
Jing WangDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, 100191, Beijing, China.
Yingtong ChenDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, 100191, Beijing, China.
Weiyou LiuDepartment of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, 341000, Ganzhou, China.
Shaoxiang LiDepartment of Pathology, Beijing Tiantan Hospital, Capital Medical University, 100070, Beijing, China.
Xiuru ZhangDepartment of Pathology, Beijing Tiantan Hospital, Capital Medical University, 100070, Beijing, China.
Gehong DongDepartment of Pathology, Beijing Tiantan Hospital, Capital Medical University, 100070, Beijing, China.
Xue HeDepartment of Pathology, Beijing Tiantan Hospital, Capital Medical University, 100070, Beijing, China. xuehe@ibms.pumc.edu.cn.
Xiaoliang YuanDepartment of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, 341000, Ganzhou, China. yxlyyxs@126.com.ORCID http://orcid.org/0000-0003-2479-0361
Hongmei JingDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, 100191, Beijing, China. hongmeijing@bjmu.edu.cn.ORCID http://orcid.org/0000-0003-4958-2489
Peking University · CNCapital Medical University · CNFirst Affiliated Hospital of Gannan Medical University · CNFujian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Megakaryocytes (MK) are mainly derived from bone marrow and are mainly involved in platelet production. Studies have shown that MK derived from bone marrow may have immune function, and that MK from peripheral blood are associated with prostate cancer. Single-cell transcriptome sequencing can help us better understand the heterogeneity and potential function of MK cell populations in bone marrow (BM), peripheral Blood (PB), and cord blood (CB) of healthy and diseased people.We integrated more than 1.2 million single-cell transcriptome data from 132 samples of PB, BM, and CB from healthy individuals and patients from different dataset. We examined the MK (including MK and product of MK) by single-cell RNA sequencing data analysis methods and identification of MK-related protein expression by the Human Protein atlas. We investigate the relationship between the MK subtype and Non-Small Cell Lung Cancer (NSCLC) in 77 non-cancer and 402 NSCLC. We found that MK were widely distributed and the amount of MK in peripheral blood was more than that in bone marrow and there were specificity MK subtypes in peripheral blood. We found classical MK1 with typical MK characteristics and non-classical MK2 closely related to immunity which was the most common subtype in bone marrow and cord blood. Classical MK1 was closely related to Non-Small Cell Lung Cancer (NSCLC) and can be used as a diagnostic marker. MK2 may have potential adaptive immune function and play a role in tumor NSCLC and autoimmune diseases Systemic Lupus Erythematosus. MK have 14 subtypes and are widely distributed in PB, CB, and BM. MK subtypes are closely related to immunity and have potential to be a diagnostic indicator of NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsBone MarrowBone Marrow CellsFetal BloodHumansMaleMegakaryocytesSequence Analysis, RNA

Identifiers

PMID35650393
OpenAlexW4281669713

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.